SUBSCRIBE

Breaking News on Food, Beverage & Supplement Development - Asia PacificEU edition | US edition

Headlines > Nutrition

Read more breaking news

 

 

Lonza and DSM settle omega-3 patent dispute

18-Feb-2014
Last updated on 20-Feb-2014 at 10:05 GMT

Lonza and DSM end decade-long patent dispute over DHA
Lonza and DSM end decade-long patent dispute over DHA

Ingredients giants DSM and Lonza have settled a patent dispute over production of algal-sourced omega-3 oils (DHA) that lasted for almost ten years.

Under the agreement, DSM Nutritional Products becomes Lonza’s supplier for its Schizochytrium-based DHA (docosahexaenoic acid) omega-3 oil.

Matthias Rüsing, global product manager for Lonza’s DHAid said that the global food supplements market would remain the focus for DHAid, not the lucrative and fast-growing infant formula space which DSM dominates via the algae DHA business it paid €800m for in the form of Martek Biosciences at the back end of 2010.

The patent dispute dates back to 2006 when Maryland-based Martek successfully sued Lonza over patent infringement relating to the US activities of the DHA business Lonza had itself just acquired from Celanese-owned Nutrinova late in 2005. It was prevented from marketing DHA there.

The global omega-3 market is estimated at €20bn+ although the US supplements market has been in slight decline in the past couple of years as negative press around some research, as well as sustainability and pricing concerns and a slow economy, have been felt.

Lonza offerings include niacin and L-carnitine.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...